Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.
about
Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune DiseasesGene therapy for brain tumors: basic developments and clinical implementationAntiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regressionComplementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancerHuman Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeuticsMarmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.Adenoviral vector-mediated gene therapy for gliomas: coming of age.Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathologyDiagnostic significance of serum HMGB1 in colorectal carcinomasGene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution.Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells.Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer modelThe art of gene therapy for glioma: a review of the challenging road to the bedsideSafety profile of gutless adenovirus vectors delivered into the normal brain parenchyma: implications for a glioma phase 1 clinical trialLife after death: targeting high mobility group box 1 in emergent cancer therapies.Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastomaPreclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma ModelHigh-mobility group box 2 is associated with prognosis of glioblastoma by promoting cell viability, invasion, and chemotherapeutic resistanceHDAC4/5-HMGB1 signalling mediated by NADPH oxidase activity contributes to cerebral ischaemia/reperfusion injury.Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.Targeting the Fas/FasL signaling pathway in cancer therapy.Glioblastoma multiforme: State of the art and future therapeutics.Chimeric adeno-associated virus and bacteriophage: a potential targeted gene therapy vector for malignant glioma.Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression.Paradoxical Role of High Mobility Group Box 1 in Glioma: A Suppressor or a Promoter?Autophagy-mediated HMGB1 release antagonizes apoptosis of gastric cancer cells induced by vincristine via transcriptional regulation of Mcl-1.Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling.The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.Consensus guidelines for the detection of immunogenic cell death.Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.
P2860
Q26768480-19AB6B3F-5702-4A6D-B74D-E8D1765EFA09Q26829086-6BD07942-DEA9-4027-B14C-0AAE452A7927Q33551268-2CFF47BC-3835-4DE5-85DB-B6DE23E70E38Q33602876-95664430-039F-4267-89D6-8B9A88B3F50BQ33605719-026302C6-99ED-4E8A-8BA7-D16E639578AFQ33828102-054600DC-5D9F-4052-B9BB-104CA556F2D5Q33828114-BBCC588D-2489-4D88-A4AC-00F18423AA61Q33877450-3B3A6842-554D-4ACE-A47F-6C9C5616ACEEQ33950709-07C44035-1C13-4060-A6B4-6A21BE4D2457Q34012284-1E403FFA-31A9-4055-9B1B-9A8E05D6019EQ34022048-2AFFDC80-769A-43B3-9353-63D902463464Q34069598-C9C15A47-B13E-49D0-977F-BBBB9EF8BA48Q34230026-F228D7F8-E948-47BB-B00F-3E21631A7356Q34359268-BBB209C9-EF03-42D6-9D4C-3B44DA419DFFQ35140121-3FDB2628-7157-4D2F-99C7-81403D70E2CFQ35161543-657269AC-0473-4FEA-A63D-AAFB18B83EE4Q35285859-947AA7E8-017E-4DE6-B52F-03E01FC5D910Q35444346-692E43C2-70EB-49F3-9CF3-E137D59019F2Q35527165-D47F30A5-EE57-487C-8E8E-0E8F096231AAQ36200438-829C1ABE-D52B-4F1D-9F07-72EC86F67ED6Q36345439-063F0C89-801E-44A0-A766-380D9CCDF9BCQ36527593-F7084A1F-3077-486C-9995-854CC84B1CAFQ36534329-505D08A6-7A4B-4F9B-908B-6BF837773284Q36562901-F8DC6600-5CEB-4F2B-8CBE-C926F2911B3AQ36811505-2B102108-6F4F-4CAD-AB47-FBFE081278EFQ37050094-24265AEB-0C71-4617-95A1-F35ADE401FBBQ37109252-726701CE-AEE2-4CD0-B1A1-74518DF3587FQ37294132-97BA3D68-5328-4269-8901-111472829AB0Q37647868-9F51AE85-166F-406E-A934-D1C040BCC0B3Q37975245-A4716781-8DB5-4F65-8FF9-5768FD993C3AQ38225874-94E851CC-188C-40E9-9E6C-FA5F18C9F45FQ38265614-C84AA43B-7463-4858-9ABC-E98B2985B8DDQ38855171-905D482A-03EB-44E4-A869-6448947E0C0DQ39223354-F5212B39-BE6A-44C9-B116-C62BEF796C08Q39438867-A25DDDC7-F698-487F-BACC-9D9363F83650Q39539596-EA5FE9FC-1ACF-45EF-8BD2-BC792AF34CEAQ41189810-30B24590-972D-44E3-926F-A1305ED8817DQ42553556-775957CD-6EE0-4866-9178-62C4E4F08480Q45864012-8F6A3DDD-9376-42D6-BD1E-A3AE0195A666Q47318878-3725866A-628E-4DCD-891C-74E87743975A
P2860
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Release of HMGB1 in response t ...... s: efficacy and neurotoxicity.
@en
Release of HMGB1 in response t ...... s: efficacy and neurotoxicity.
@nl
type
label
Release of HMGB1 in response t ...... s: efficacy and neurotoxicity.
@en
Release of HMGB1 in response t ...... s: efficacy and neurotoxicity.
@nl
prefLabel
Release of HMGB1 in response t ...... s: efficacy and neurotoxicity.
@en
Release of HMGB1 in response t ...... s: efficacy and neurotoxicity.
@nl
P2093
P2860
P1476
Release of HMGB1 in response t ...... s: efficacy and neurotoxicity.
@en
P2093
A K M Ghulam Muhammad
Chunyan Liu
David Foulad
Gabrielle E Alzadeh
Gwendalyn D King
James F Curtin
Jonathan Lerner
Kader Yagiz
Katsuaki Sato
Kurt M Kroeger
P2860
P304
P356
10.1158/1078-0432.CCR-09-0155
P407
P577
2009-07-01T00:00:00Z